Company intelligence

NEO

NeoGenomics, Inc. · NASDAQ · Healthcare

Price$16.79+2.32% · +$0.38

Market cap431.42MEquity value

P / E129.2Trailing ratio

Volume872.1KLatest session

Market data

NEO price chart

TradingView

Related signals

1 min delayed

Browse public NEO signals with their source context and measured market impact. Open any signal for its permanent analysis page.

NEOSep 17, 2025+8.02% since signal

NeoGenomics Stock In A Range-Bound Matrix, Weakness Likely Until 2026

NEO is in Phase 18, consolidating for over 850 days. Signs of a breakout remain weak until at least August 2026. Historical trends show risk of declining to $18 price level. Weak Guna Triads indicate lack of bullish momentum. Investors should hold off on new positions in NEO.

View signal analysis

NEOAug 29, 2025-1.68% since signal

NeoGenomics Gains 'Unexpected' Win As Court Rejects Natera Claims

Court ruling invalidates Natera's patents against NeoGenomics' RaDaR test. NeoGenomics can commercialize RaDaR ST assay, enhancing market prospects. Stock surged 24.55% after positive court decision and analyst outlook. Launch for RaDaR ST expected in Q4 2025, boosting investor confidence. William Blair maintains Market Perform rating citing execution confidence needed.

View signal analysis

Research